This characteristic has allowed researchers to study its systemic biological effects across multiple experimental models
BPC-157 isnt approved as a drug in any country, and isnt available for compounding
Containing 0.9% benzyl alcohol, each finished batch is independently tested for sterility and supplied in a sealed 20ml borosilicate glass vial with full lot traceability
BPC-157 is described in research as unusually robust for a peptide, including documented stability in gastric juice (around pH 1.5) and across a broad pH range
Theres no DEA registration requirement, no prescription monitoring program reporting, and no special licensing hurdle for your provider which is part of why peptide therapy can move quickly once the FDA opens the compounding pathway
[1] Testing Grounds: The Trials and Outcomes of AOD-9604 AOD-9604's lipolytic potential has made it a compelling molecule for scientists and medical professionals looking to harness its potential for therapeutic purposes